drugset / Trial / NCT01823315

Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia

NCT01823315

RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators conducted a trial to determine whether methotrexate or methotrexate/dactinomycin single-course treatment work well as multiple courses of single methotrexate chemotherapy in low-risk gestational trophoblastic neoplasia. It is not yet known whether single-course of chemotherapy is as the same effectiveness as multicourse.

Timeline

Start
2012-12
Primary completion
2015-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dactinomycin Protein / enzyme biologic 0.6 mg/m2 Intravenous
Subject Methotrexate Small molecule 0.4 mg/kg Intramuscular
Subject Methotrexate Small molecule 100 mg/m2 Intramuscular
Subject Methotrexate Small molecule 200 mg/m2 Intramuscular